FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides

FDA has directed the manufacturers of all drug products approved for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) to develop patient Medication Guides to alert patients to possible cardiovascular risks and risks of adverse psychiatric symptoms associated with the medicines, and to advise them of precautions that can be taken.

• FDA Press Release (issued February 21, 2007)
• Advisory Committee Transcripts
  • Drug Safety and Risk Management Advisory Committee, February 9, 2006
  • Pediatric Advisory Committee, March 22, 2006

Drugs

Note: This page links to PDF files which require the free Adobe Acrobat Reader.